Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives
JSFA reports · 2026-11 · 6 (11) · 473-489
DOI: 10.1002/jsf2.70079 ↗Kurz gefasst
Fachartikel in der Zeitschrift JSFA reports, online erschienen am 14.07.2026. Verfasst von Muhammad Maaz und 10 weiteren Autor:innen. Die Arbeit nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer is constantly rising mortality rates due to its late prognosis, poor management, and expensive treatment. Multi‐sectoral approaches for cancer management include hygienic practices, synthetic drug exploitation, radiation therapy, and diet modifications. Healthcare professionals and dietitians work as a team to reduce cancer malignancy and severity. It has been observed that certain pathways (mTOR/AKT, EMT, EGFR/ERK1, and Rap/PI3K‐Akt) and gene expressions (CDK2, CCNB1, PCNA, PRIM1, and ATF6) are involved, which contribute to exaggerating metastatic activity within the individual body. Medicinal plants and bioactive compounds, particularly berberine, inhibit cancer metastasis. Moreover, its bioavailability has significant potential, which is improved by D‐α‐tocopheryl polyethylene glycol 1000 succinate, lysergol, and by formulating nano‐emulsions and nano‐drugs. Furthermore, its antioxidant potential is associated with the aggravating levels of SOD, GPx, and MDA. Berberine inhibited cancer cell proliferation, migration, and invasion by inducing apoptosis and targeting cancer‐promoting pathways and expressions. Although significant research related to the anticancer potentials is available, there are certain limitations, such as mechanistic randomized clinical trials, berberine bioavailability, and its future applications in functional foods and nutraceuticals, which need to be conducted.
Zitieren
APA
Maaz, M., Sultan, M. T., Israr, M., Khan, W. A., Tanveer, F., Hussain, M., Imran, M., Mujtaba, A., Memon, A. G., Atif, M., & Jbawi, E. A. (2026). Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives. JSFA reports, 6(11), 473-489. https://doi.org/10.1002/jsf2.70079
Vancouver
Maaz M, Sultan MT, Israr M, Khan WA, Tanveer F, Hussain M, et al. Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives. JSFA reports. 2026;6(11):473-489. doi:10.1002/jsf2.70079
BibTeX
@article{Maaz2026,
author = {Maaz, Muhammad and Sultan, Muhammad Tauseef and Israr, Muhammad and Khan, Waqas Ahmad and Tanveer, Fahad and Hussain, Muzzamal and Imran, Muhammad and Mujtaba, Ahmed and Memon, Anjuman Gul and Atif, Muhammad and Jbawi, Entessar Al},
title = {Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives},
journal = {JSFA reports},
year = {2026},
volume = {6},
number = {11},
pages = {473--489},
doi = {10.1002/jsf2.70079}
}
EUVIMED